Guggenheim Initiates Coverage of Ovid Therapeutics with Buy Rating, $7 Price Target
Guggenheim has initiated coverage of Ovid Therapeutics with a 'Buy' rating and set a price target of $7.00 per share.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.